Abstract

SESSION TITLE: DVT/PE Posters

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Although fondaparinux is recommended by experts for the treatment of heparin- induced thrombocytopenia (HIT), recent guidelines from the American College of Chest Physicians do not support its use. In light of the aforementioned uncertainties, we conducted a systematic review to assess outcomes in HIT patients treated with fondaparinux.

METHODS: We searched electronic databases and meeting abstract books (Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE) for relevant articles reporting the outcome of patients treated with fondaparinux for serologically proven HIT. Two reviewers independently assessed the eligibility of all the articles identified in the initial search strategy. The main outcome of the study was new thrombotic events (venous or arterial) during acute treatment with fondaparinux, secondary outcomes included death, amputation and major bleeding. Pooled proportions and odds ratios (OR) were calculated using a random effect model for fondaparinux alone or compared to other alternative anticoagulants. Heterogeneity was measured using I2, and quality was measured using the Newcastle-Ottawa scale.

RESULTS: Our search retrieved 2034 articles of which 26 were further reviewed. Nine studies reporting on 151 patients treated with fondaparinux for HIT (61% of them with a thrombotic complication) were included. No randomized trials were identified, seven studies were retrospective and three studies compared fondaparinux (36 patients) and lepirudin (37 patients). The pooled proportion of new thrombosis in patients treated with fondaparinux was 3.3% (1.1-6.8;I2 4.2%) and the pooled proportion of major bleeding was 4.9% (2.1-8.8;I2 0%). One amputation and no treatment associated deaths occurred in patients treated with fondaparinux. In three studies comparing fondaparinux vs. lepirudin no differences were identified in the rate of thrombosis OR 0.69 (0.12 3.89; I2 0% ) or bleeding OR 0.82 (0.11-5.86; I2 0%). The quality of the studies included was low to moderate.

CONCLUSIONS: Limited evidence from observational studies suggests that fondaparinux could be an alternative anticoagulant for the treatment of HIT.

CLINICAL IMPLICATIONS: Compared to alternative anticoagulants used for the treatment of HIT, fondaparinux is easy to administer, does not require routine laboratory monitoring, and is relatively inexpensive. Our results call for studies comparing fondaparinux to alternative anticoagulants in patients with HIT.

Return to: Efficacy and Safety of Fondaparinux for the Management of Patients With Heparin-Induced Thrombocytopenia: A Systematic Review

Copyright in the material you requested is held by the American College of Chest Physicians (unless otherwise noted).
This email ability is provided as a courtesy, and by using it you agree that that you are requesting the material
solely for personal, non-commercial use, and that it is subject to the American College of Chest Physicians’ Terms of Use.
The information provided in order to email this topic will not be used to send unsolicited email, nor will it be
furnished to third parties. Please refer to the American College of Chest Physicians’ Privacy Policy for further information.

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username
(required)

Email Address
(required)

Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.